Sam Brusco, Associate Editor02.18.22
Globus Medical yesterday reported fourth quarter and full-year 2021 financial results.
The company reported $250 million in sales last quarter, rising 7.1 percent over Q4 2020. U.S. sales increased 7.2 percent, and international sales rose 6.8 percent in the final quarter as well.
Worldwide sales totaled $958.1 million, a whopping 21.4 percent increase over the full year of 2020. Non-GAAP diluted EPS for 2021 was $2.04.
Globus expects net sales to top $1 billion next year and have a non-GAAP diluted earnings per share of $2.10.
“Our fourth quarter results topped off another record-breaking year for Globus Medical, as we continued to perform well above our peers in growth as well as profitability,” Dave Demski, Globus president and CEO told the press. “The clinical superiority of ExcelsiusGPS continues to be the primary factor driving Enabling Technology momentum, which produced a record $25 million in revenue for the fourth quarter and $81 million for 2021, a 100 percent increase over 2020. Musculoskeletal Solutions also completed another outstanding year of market-share gains, led by US Spine with 18 percent growth, International Spine with 12 percent growth and Trauma with 39 percent growth. I want to thank all of our customers and team members for their belief and support and look forward to a very bright future together.”
The company reported $250 million in sales last quarter, rising 7.1 percent over Q4 2020. U.S. sales increased 7.2 percent, and international sales rose 6.8 percent in the final quarter as well.
Worldwide sales totaled $958.1 million, a whopping 21.4 percent increase over the full year of 2020. Non-GAAP diluted EPS for 2021 was $2.04.
Globus expects net sales to top $1 billion next year and have a non-GAAP diluted earnings per share of $2.10.
“Our fourth quarter results topped off another record-breaking year for Globus Medical, as we continued to perform well above our peers in growth as well as profitability,” Dave Demski, Globus president and CEO told the press. “The clinical superiority of ExcelsiusGPS continues to be the primary factor driving Enabling Technology momentum, which produced a record $25 million in revenue for the fourth quarter and $81 million for 2021, a 100 percent increase over 2020. Musculoskeletal Solutions also completed another outstanding year of market-share gains, led by US Spine with 18 percent growth, International Spine with 12 percent growth and Trauma with 39 percent growth. I want to thank all of our customers and team members for their belief and support and look forward to a very bright future together.”